Edition:
United States

People: Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

11.48EUR
29 Sep 2016
Change (% chg)

-- (--)
Prev Close
€11.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
213,481
52-wk High
€16.20
52-wk Low
€10.00

Hansen, Bo 

Dr. Bo Jesper Hansen, M.D., Ph.D., is Independent Director of Ablynx NV. He is the permanent representative of Orfacare Consulting, currently serves as Executive Chairman of the Board of SOBI AB (Swedish Orphan Biovitrum AB). He is Chairman of Karolinska Development AB and is also non-executive Director of a number of biotech and pharma companies including Orphazyme ApS, Newron Pharmaceuticals SpA, CMC AB, Hyperion Therapeutics Inc. and Genspera Inc. Dr Hansen served as CEO and President and as Director to the Board of Swedish Orphan International until the merger with Biovitrum, forming Swedish Orphan Biovitrum. He also was non-executive Director of Gambro until its acquisition by Baxter, and Zymenex, until its acquisition by Chiesi. Dr. Hansen was the Executive Chairman of Topotarget and in this role led the merger with BioAlliance forming OnXeo. He founded Scandinavian Medical Research during which he served as Medical Advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --